SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    O'Day SJ, Kim CJ, Reintgen DS. Metastatic melanoma: chemotherapy to biochemotherapy. Cancer Control. 2002; 9: 3138.
  • 2
    Anderson CM, Buzaid AC, Legha SS. Systemic treatments for advanced cutaneous melanoma. Oncology. 1995; 9: 11491158.
  • 3
    Fisher RI, Neifeld JP, Lippman ME. Estrogen receptors in human malignant melanoma. Lancet. 1976; 2: 337338.
  • 4
    Walker MJ, Beattie CW, Patel MK, Ronan SM, Das Gupta TK. Estrogen receptor in malignant melanoma. J Clin Oncol. 1987; 5: 12561261.
  • 5
    Flowers JL, Seigler HF, McCarty KS Sr., Konrath J, McCarty KS Jr. Absence of estrogen receptor in human melanoma as evaluated by a monoclonal antiestrogen receptor antibody. Arch Dermatol. 1987; 123: 764765.
  • 6
    Toma S, Ugolini D, Palumbo R. Tamoxifen in the treatment of metastatic malignant melanoma: still a controversy? Int J Oncol. 1999; 15: 321337.
  • 7
    Nesbit RA, Woods RL, Tattersall MH, et al. Tamoxifen in malignant melanoma. N Engl J Med. 1979; 301: 12411242.
  • 8
    Del Prete SA, Maurer LH, O'Donnell J, Forcier RJ, LeMarbra P. Combination chemotherapy with cisplatin, carmustine, dacarbazine and tamoxifen in metastatic melanoma. Cancer Treat Rep. 1984; 68: 14031405.
  • 9
    Rusthoven JJ. The evidence for tamoxifen and chemotherapy as treatment for metastatic melanoma. Eur J Cancer. 1998; 34(Suppl 3): S31S36.
  • 10
    Cocconi G, Bella M, Calabresi F, et al. Treatment of metastatic malignant melanoma with decarbazine plus tamoxifen. N Engl J Med. 1992; 327: 516523.
  • 11
    Legha S, Ring S, Bedikian A, et al. Lack of benefit from tamoxifen (T) added to a regimen of cisplatin (C), vinblastine (V), DTIC (D) and alpha interferon (IFN) in patients with metastatic melanoma [abstract]. Proc Am Soc Clin Oncol. 1993; 1325a.
  • 12
    Rusthoven JJ, Quirt IC, Iscoe NA, et al. Randomized, double-blind, placebo controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. J Clin Oncol. 1996; 14: 20832090.
  • 13
    Agarwala SS, Ferri W, Gooding W, Kirkwood JM. A Phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma. Cancer. 1999; 85: 19791984.
  • 14
    Falkson CI, Ibrahim J, Kirkwood JN, Coates AS, Atkins MB, Blum RH. Phase III trial of dacarbazine versus dacarbazine with interferon α-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon α-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group Study. J Clin Oncol. 1998; 16: 17431751.
  • 15
    Creagan ET, Suman VJ, Dalton RJ, et al. Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma. J Clin Oncol. 1999; 17: 18841890.
  • 16
    Moher D, Cock DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUORUM statement. Lancet. 1999; 354: 18961900.
  • 17
    Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet. 2001; 357: 11911194.
  • 18
    Juni P, Altman DG, Egger M. Systematic reviews in healthcare: assessing the quality of controlled clinical trials. BMJ. 2001; 323: 4246.
  • 19
    McClay EF, McClay ME, Monroe L, et al. The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma. Br J Cancer. 2000; 83: 1621.
  • 20
    McClay EF, McClay MT, Monroe L, Jones JA, Winski PJ. A Phase II study of high dose tamoxifen and weekly cisplatin in patients with metastatic melanoma. Melanoma Res. 2001; 11: 309313.